Hepatitis E Vaccine Works in Chinese Study, May Fight ‘Scourge’
This article is for subscribers only.
An experimental vaccine prevented hepatitis E in all patients who received it in a study, making it a crucial development in combating the “scourge” of the virus, the U.S. Centers for Disease Control and Prevention said.
More than 112,000 healthy people age 16 to 65 from Jiangsu province in China participated in the 19-month trial of Xiamen, China-based Xiamen Innovax Biotech Co.’s HEV 239 vaccine. None of the patients who got the vaccine had the disease 30 days after the last of three doses was administered, according to the study published in The Lancet medical journal today.